OTHER INFORMATION
+Added: Director Departure
+Added: On August 7, 2023, Douglas Cole, M.D.
+Added: submitted his resignation from Denali's Board of Directors and the Compensation Committee on which he served.
+Added: Cole's resignation was voluntary and did not result from any disagreement with Denali or its Board of Directors.
+Added: The Denali Board thanks Dr.
+Added: Cole for his impactful service over the past eight years as a founding investor and member of the Denali Board.
+Added: Securities Trading Plans of Directors and Executive Officers
+Added: No officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the period from April 1, 2023 through June 30, 2023 .
EXHIBIT INDEX
21 unchanged sentences
— — — Furnished herewith
−Removed: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2023, formatted in Inline XBRL (contained in Exhibit 101)
+Added: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2023, formatted in Inline XBRL (contained in Exhibit 101)
— — — Furnished herewith
3 unchanged sentences
DENALI THERAPEUTICS INC.
−Removed: May 8, 2023 By:
+Added: August 8, 2023 By:
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: May 8, 2023 By:
+Added: August 8, 2023 By:
/s/ Alexander O.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.